Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum
- PMID: 11389733
- DOI: 10.1046/j.1432-1327.2001.02233.x
Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum
Abstract
To date, relative cellular levels of cGMP and cGMP-binding proteins have not been considered important in the regulation of smooth muscle or any other tissue. In rabbit penile corpus cavernosum, intracellular cGMP was determined to be 18 +/- 4 nM, whereas the cGMP-binding sites of types Ialpha and Ibeta cGMP-dependent protein kinase (PKG) and cGMP-binding cGMP-specific phosphodiesterase (PDE5) were 58 +/- 14 nM and 188 +/- 6 nM, respectively, as estimated by two different methods for each protein. Thus, total cGMP-binding sites (246 nM) greatly exceed total cGMP. Given this excess of cGMP-binding sites and the high affinities of PKG and PDE5 for cGMP, it is likely that a large portion of intracellular cGMP is associated with these proteins, which could provide a dynamic reservoir for cGMP. Phosphorylation of PDE5 by PKG is known to increase the affinity of PDE5 allosteric sites for cGMP, suggesting the potential for regulation of a reservoir of cGMP bound to this protein. Enhanced binding of cGMP by phosphorylated PDE5 could reduce the amount of cGMP available for activation of PKG, contributing to feedback inhibition of smooth muscle relaxation or other processes. This introduces a new concept for cyclic nucleotide signaling.
Similar articles
-
Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.Mol Pharmacol. 1999 Jul;56(1):124-30. doi: 10.1124/mol.56.1.124. Mol Pharmacol. 1999. PMID: 10385692
-
Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities.Eur J Biochem. 2000 May;267(9):2760-7. doi: 10.1046/j.1432-1327.2000.01297.x. Eur J Biochem. 2000. PMID: 10785399
-
Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle.Biochem J. 2001 Nov 15;360(Pt 1):199-208. doi: 10.1042/0264-6021:3600199. Biochem J. 2001. PMID: 11696008 Free PMC article.
-
Mechanisms of action of PDE5 inhibition in erectile dysfunction.Int J Impot Res. 2004 Jun;16 Suppl 1:S4-7. doi: 10.1038/sj.ijir.3901205. Int J Impot Res. 2004. PMID: 15224127 Review.
-
Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.Urology. 2002 Sep;60(2 Suppl 2):4-11. doi: 10.1016/s0090-4295(02)01686-2. Urology. 2002. PMID: 12414329 Review.
Cited by
-
Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.Cell Signal. 2009 Dec;21(12):1768-74. doi: 10.1016/j.cellsig.2009.07.012. Epub 2009 Aug 6. Cell Signal. 2009. PMID: 19665054 Free PMC article.
-
Melatonin inhibits nitric oxide signaling by increasing PDE5 phosphorylation in coronary arteries.Am J Physiol Heart Circ Physiol. 2012 Dec 15;303(12):H1418-25. doi: 10.1152/ajpheart.00211.2012. Epub 2012 Oct 19. Am J Physiol Heart Circ Physiol. 2012. PMID: 23086989 Free PMC article.
-
Sickling cells, cyclic nucleotides, and protein kinases: the pathophysiology of urogenital disorders in sickle cell anemia.Anemia. 2012;2012:723520. doi: 10.1155/2012/723520. Epub 2012 Jun 13. Anemia. 2012. PMID: 22745902 Free PMC article.
-
Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone.World J Urol. 2004 Oct;22(4):261-6. doi: 10.1007/s00345-003-0394-4. Epub 2004 Mar 26. World J Urol. 2004. PMID: 15045518
-
Mathematical Modelling of Nitric Oxide/Cyclic GMP/Cyclic AMP Signalling in Platelets.Int J Mol Sci. 2018 Feb 19;19(2):612. doi: 10.3390/ijms19020612. Int J Mol Sci. 2018. PMID: 29462984 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources